AU2809899A - Dosing beverage with a bacteria formulation - Google Patents
Dosing beverage with a bacteria formulation Download PDFInfo
- Publication number
- AU2809899A AU2809899A AU28098/99A AU2809899A AU2809899A AU 2809899 A AU2809899 A AU 2809899A AU 28098/99 A AU28098/99 A AU 28098/99A AU 2809899 A AU2809899 A AU 2809899A AU 2809899 A AU2809899 A AU 2809899A
- Authority
- AU
- Australia
- Prior art keywords
- containers
- formulated
- beverage
- mixture
- probiotic bacteria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241000894006 Bacteria Species 0.000 title claims description 48
- 235000013361 beverage Nutrition 0.000 title claims description 39
- 239000000203 mixture Substances 0.000 title claims description 39
- 238000009472 formulation Methods 0.000 title description 15
- 239000006041 probiotic Substances 0.000 claims description 32
- 230000000529 probiotic effect Effects 0.000 claims description 32
- 235000018291 probiotics Nutrition 0.000 claims description 32
- 235000013336 milk Nutrition 0.000 claims description 25
- 210000004080 milk Anatomy 0.000 claims description 25
- 239000008267 milk Substances 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 21
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 20
- 235000013406 prebiotics Nutrition 0.000 claims description 16
- 241000894007 species Species 0.000 claims description 13
- 241000186000 Bifidobacterium Species 0.000 claims description 9
- 241000186660 Lactobacillus Species 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 235000013325 dietary fiber Nutrition 0.000 claims description 6
- 229920001542 oligosaccharide Polymers 0.000 claims description 6
- 150000002482 oligosaccharides Chemical class 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 235000015203 fruit juice Nutrition 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229920002774 Maltodextrin Polymers 0.000 claims description 2
- 239000005913 Maltodextrin Substances 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
- 230000012010 growth Effects 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 229940035034 maltodextrin Drugs 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 230000007246 mechanism Effects 0.000 description 9
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 8
- 229940107187 fructooligosaccharide Drugs 0.000 description 8
- 235000015205 orange juice Nutrition 0.000 description 6
- 238000000151 deposition Methods 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229940039696 lactobacillus Drugs 0.000 description 3
- 235000020200 pasteurised milk Nutrition 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 241000186016 Bifidobacterium bifidum Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000004207 intestinal integrity Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002991 molded plastic Substances 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Description
AUSTRALIA
Patents Act 1990 COMPLETE SPECIFICATION DIVISIONAL PATENT Applicant: THE MENDEL INSTITUTE FOR NUTRACEUTICAL RESEARCH,
INC
Invention Title: DOSING BEVERAGE WITH A BACTERIA FORMULATION The following statement is a full description of this invention, including the best method of performing it known to me/us: DOSING BEVERAGE WITH A BACTERIA
FORMULATION
FIELD OF THE INVENTION This invention relates to a method of and apparatus for use in adding a probiotic bacteria formulation to a beverage.
The invention has been developed primarily in the context of dosing milk liquid milk in its various possible forms, including soy milk) with a probiotic bacteria formulation and the invention is hereinafter described in this context. However, it will be understood that the invention does have broader application, to the dosing of other beverages and to dosing with a formulation that contains substances additional to probiotic bacteria.
BACKGROUND OF THE INVENTION The benefits of dosing food products, including milk products, with bacteria are well known. Documented examples of the beneficial effects of the use of certain bacterial strains Lactobacillus and Bifidobacterium strains) include their treatment of various types of diarrhoea, the alleviation of the gastrointestinal side effects of antibiotic treatment, the alleviation of lactose intolerance, the relief of constipation and the general balancing and stabilisation of intestinal integrity. More recent studies have indicated that, for some strains, immune-enhancing and vaccine-adjuvant effects have been obtained, and an ability to lower serum cholesterol has been observed. Some bacterial strains also have shown an ability to suppress tumour growth and to remove or modify dietary carcinogens. In addition, some strains have also been shown to produce vitamins and, in particular, the important B group vitamins including folic acid. Other benefits to be derived from the administration of bacteria are enhanced bioabsorption of minerals, particularly J:\Speci\300 399\300 349\34296.doc 11/05/99 calcium and iron from dietary components. These therapeutic effects are in addition to the well-known nutritional effects that flow from improvement in the digestion of proteins and fats in food products.
Health promoting foods, such as yoghurt, that contain probiotic and, in some cases, prebiotic bacteria currently are available. However, these food products do not find favour with some consumers because of their sour, lactic taste, and the addition of a sweetening agent is often undesirable.
It is recognised by persons who have an interest in public health that a broadly based supplementation of probiotic bacteria intake would provide community benefit. In this context consideration has been given to the introduction of probiotic bacteria into milk, this being one of the most widely consumed food products in many communities.
A probiotic therapeutic benefit may be obtained from a minimum daily intake in the order of 1 x 109 colony forming units (cfu) but, because of the extremely small mass that is represented by this volume, controlled community administration presents a significant problem. Some milks have been made available which contain lactic bacterial cultures. However they are produced by adding a very small dose (by volume) of the cultures to a large volume of milk in a refrigerated mixing vessel. The milk containing the lactic cultures is dispensed into individual retailing sized containers by way of filling machinery but, because of the relatively small volume of bacteria present in the milk supply, the statistical likelihood of a therapeutic amount of probiotic bacteria being dosed into each container is extremely low.
The present invention seeks to provide a solution to this problem.
J:\Speci\300 399\300 349\34296.doc 11/05/99 SUMMARY OF THE INVENTION Broadly defined, the present invention provide a method of adding a probiotic bacteria to a beverage and which comprises the steps of: a. formulating a mixture of the bacteria and a biologically acceptable beverage-miscible excipient, b. delivering empty beverage containers to a filling station and conveying the containers serially through the filling station, c. delivering a predetermined quantity of the formulated mixture to each container whilst it is positioned within the filling station and, as a separate operation, d. injecting a predetermined quantity of the beverage into each of the containers.
The formulated mixture containing the probiotic bacteria and excipient may be delivered to each container in a liquid form or in a tablet form. However, in either case, the beverage is injected separately from delivery of the formulated mixture, always from separate sources and normally at different instants in time.
The containers into which the bacteria/excipient formulation and the beverage are delivered may comprise glass or plastic bottle-type containers or cardboard containers of the type in which milk and fruit beverages frequently are marketed.
The beverage delivering mechanism may take any one of the forms that currently are employed for delivering beverages to containers. These normally are integrated in high speed production lines in which filling and container closing or capping processes occur and, in order to minimise any reduction in the transport velocity of a production line, the containers may temporarily be diverted from a main conveyor system to a secondary conveyor system. Delivery J:\Speci\300 399\300 349\34296.doc 11/05/99 of the liquid or tablet form bacteria/excipient formulation to successive ones of the containers may then be effected whilst the containers are conveyed by the secondary conveyor, without interfering with the overall system transport velocity.
PREFERRED FEATURES OF THE INVENTION The beverage preferably is injected into the beverage containers at the same time as or after delivery of the formulated mixture, in order to promote dispersion of the formulated mixture throughout the beverage.
The probiotic bacteria preferably is selected from a group comprising lactobacilli and bifidobacteria.
The probiotic bacteria most preferably comprises lactobacilli acidophillus, bifidobacteria bifidus and/or bifidobacteria infantis.
The formulated mixture preferably includes a blend of the probiotic bacteria and a prebiotic substance, most preferably a prebiotic soluble dietary fibre selected for promoting growth of the probiotic bacteria in the human gastro-intestinal tract.
The prebiotic substance, when included, may comprise an oligosaccharide and, preferably, fructooligosaccharide.
In circumstances where the beverage to which the bacteria/excipient formulation is added comprises milk, the excipient preferably comprises milk, an oligosaccharide, lactose or maltodextrin.
As indicated previously, the probiotic bacteria may be added to beverages other than milk, for example fruit juices. In these circumstances the excipient preferably J:\Speci\300 399\300 349\34296.doc 11/05/99 comprises a fruit juice or an oligosaccharide.
The formulated mixture containing the probiotic bacteria may include therapeutically or prophylatically beneficial additives, for example immunoglobulins or phytoestrogens and other ingredients of the type commonly added to milk and other beverages.
EXAMPLES OF BACTERIA/EXCIPIENT
FORMULATIONS
The following example is provided in relation to the formulating and mixing of material to be added in a liquid form to milk.
To 10 litres of pasteurised milk there are added A stabilised probiotic bacteria consisting of bifidobacterium bifidum 12 x 1012cfu lactobacillus acidophillus 4 x 1012cfu.
(ii) Prebiotic dietary fibre consisting of fructooligosaccharide 2 x 10 3 gms.
The components are aseptically mixed until solids are fully dissolved. The resultant solution is supplied to a reservoir of an injector mechanism which is controlled to deliver the solution to milk containers in the amount of per litre of milk to be dispensed into the containers.
After receiving the solution, each container is moved forward to a milk dispensing station where it is filled to the required level with milk.
Each container of milk containing the probiotic bacteria and solubilised prebiotic fructooligosaccharide is then closed and refrigerated prior to distribution.
The following example is provided in relation to the J:\Speci\300 399\300 349\34296.doc 11/05/99 formulating and mixing of material to be added in tablet form (at the rate of one tablet per litre of milk) to pasteurised milk.
A tabletting mixture containing the following is prepared: Stabilised probiotic bacteria consisting of bifidobacterium bifidus 60 x 101cfu lactobacillus acidophilus 20 x 10 12 cfu.
(ii) Prebiotic dietary fibre excipient consisting of compressable, soluble fructooligosaccharide x 10 3 gms.
The ingredients are dry-blended and fed to the hopper of a tablet forming machine which is fitted with a die that is sized and constructed to produce individual tablets having substantially uniform weight of 3 gms.
The tables are fed to a bulk hopper of a depositing mechanism that is arranged to dispense one tablet into each of a succession of one-litre containers that are conveyed through the depositing mechanism en route to a milk dispensing station.
After receiving one tablet, each container is moved into the milk dispensing station where it receives one litre of pasteurised milk.
Each container of milk containing the probiotic bacteria and solubilised prebiotic fructooligosaccharide is then closed and refrigerated prior to distribution.
The following example is provided in relation to the formulating and mixing of material to be added in liquid form to a beverage in the form of orange juice.
J:\Speci\300 399\300 349\34296.doc 11/05/99 To 10 litres of sterile water there is added Stabilised probiotic bacterium consisting of bifidobacterium bifidum 12 x 10 12 cfu lactobacillus acidophillus 4 x 1012cfu.
(ii) Prebiotic dietary fibre consisting of fructooligosaccharide 2 x 10 3 gms.
(iii) Orange juice concentrate 10 litres.
The components are asceptically mixed until solids are fully dissolved. The resultant solution is supplied to a reservoir of an injector mechanism which is controlled to deliver the solution to beverage containers in the amount of 10 ml of the solution per litre of beverage to be dispensed into the containers.
The containers are then advanced to a beverage filling station and, assuming that each container has a 1 litre capacity, beverage in the amount of 990 ml of orange juice is dispensed into the container.
Each container of beverage containing the probiotic bacteria and solubilised prebiotic material is then closed and conveyed to cold storage prior to distribution.
The following example is provided in relation to the formulating and mixing of material to be added in tablet form to a beverage in the form of orange juice.
A tabletting mixture containing the following is prepared: Stabilised probiotic bacteria consisting of bifidobacterium bifidus 60 x 102cfu lactobacillus acidophilus 20 x 1012cfu.
(ii) Prebiotic dietary fibre excipient consisting of J:\Speci\300 399\300 349\34296.doc 11/05/99 compressable, soluble fructooligosaccharide x 10 3 gms.
The ingredients are dry-blended and fed to the hopper of a tablet forming machine which is fitted with a die that is sized and constructed to produce individual tablets having substantially uniform weight of 3 gms.
The tablets are fed to a bulk hopper of a depositing mechanism that is arranged to dispense one tablet into each of a succession of one-litre containers that are conveyed through the depositing mechanism en route to a beverage dispensing station.
After receiving one tablet, each container is moved into the beverage dispensing station where it receives one litre of orange juice.
Each container of orange juice containing the probiotic bacteria and solubilised prebiotic fructooligosaccharide is then closed and conveyed to cold storage prior to distribution.
DETAILED DESCRIPTION OF APPARATUS FOR DELIVERING BACTERIA/EXCIPIENT FORMULATION The invention will be more fully understood from the following description of a preferred embodiment of an apparatus for use in delivering a bacteria/excipient formulation to beverage containers. The description is provided with reference to the accompanying schematic drawing.
The apparatus as illustrated in the drawing is intended for use in delivering a liquid form bacteria/excipient formulation into moulded plastics beverage containers The containers are delivered to the apparatus by a primary J:\Speci\300 399\300 349\34296.doc 11/05/99 conveyor 11 which forms a part of a high speed container filling/capping station. Although three only containers are shown, the apparatus would normally be operated to receive tightly bunched containers by way of the conveyor 11, and twelve containers 10 would normally be positioned on a carousel-type secondary conveyor 12 at any one point in time.
Empty containers 10 are delivered to the apparatus in the direction of arrow 13 and are deflected off the primary conveyor 11 by an in-feed starwheel mechanism 14. That is, the empty containers are deflected onto a lower rotary platform 15 of the carousel 12 and they are moved in a circular path until they meet an out-feed starwheel mechanism 16 which is driven to redeflect the containers back onto the primary conveyor 11.
Having been directed from and then back onto the primary conveyor 11, the containers 10 are transported in the direction of arrow 17 to a beverage filling station (not shown) of a conventional type.
In addition to the rotary platform 15, the secondary conveyor 12 incorporates an upper rotary platform 18 which carries three pumping systems 19. Each pumping system incorporates a peristaltic pump which is driven to deliver periodic doses in a predetermined amount of bacteria/excipient formulation through four delivery lines The delivery lines 20 are coupled to respective injectors 21 which, in use, are activated to inject the predetermined amount of the bacteria/excipient formulation into the containers 10 during the time that the containers are conveyed in the circular path around the carousel 12.
J:\Speci\300 399\300 349\34296.doc 11/05/99 A control panel 22 is provided for exercising electrical/electronic control over the apparatus in conjunction with further control systems (not shown) associated with the container feeding system.
A similar type of apparatus may be used when delivering tablet-form bacteria/excipient formulations into beverage containers. However, in such a case the apparatus will provide for the deposition of a single (preformed) tablet into each container whilst the containers are being transported around the secondary conveyor 12. For this purpose, a vibratory bowl feeder (not shown) may be mounted upon the upper rotary platform 18 of the apparatus and be arranged to feed individual tablets serially to each of a plurality of tablet releasing heads (not shown) located around the rotary platform of the secondary conveyor.
J:\Speci\300 399\300 349\34296.doc 11/05/99
Claims (14)
- 2. The method as claimed in claim 1 wherein the formulated mixture containing the probiotic bacteria and the excipient is delivered to each container in a liquid form.
- 3. The method as claimed in claim 1 wherein the formulated mixture containing the probiotic bacteria and the excipient is delivered to each container in a tablet form.
- 4. The method as claimed in any one of claims 1 to 3 wherein the beverage is injected into each container after delivery of the formulated mixture to the container. The method as claimed in any one of claims 1 to 4 wherein the beverage comprises milk.
- 6. The method as claimed in any one of claims 1 to 4 wherein the beverage comprises a fruit juice.
- 7. The method as claimed in any one of claims 1 to 6 wherein the mixture is formulated from a probiotic bacteria selected from a group comprising lactobacilli and bifidobacteria.
- 8. The method as claimed in any one of claims 1 to 7 J:\Speci\300 399\300 349\34296.doc 11/05/99 wherein the mixture is formulated from a probiotic bacteria comprising lactobacilli acidophi-llus, bifidobacteria bifidus and/or bifidobacteria infantis.
- 9. The method as claimed in any one of claims 1 to 8 wherein the mixture is formulated to include a blend of the probiotic bacteria and a prebiotic substance. The method as claimed in claim 9 wherein the prebiotic substance comprises a prebiotic soluble dietary fibre selected for promoting growth of the probiotic bacteria in the human gastro-intestinal tract.
- 11. The method as claimed in claim 10 wherein the prebiotic substance comprises an oligosaccharide.
- 12. The method as claimed in claim 5 wherein the mixture is formulated with the excipient composed of milk, an oligosaccharide, lactose and/or maltodextrin.
- 13. The method as claimed in claim 6 wherein the mixture is formulated with the excipient composed of a fruit juice and/or an oligosaccharide.
- 14. The method as claimed in any one of claims 1 to 13 wherein injection of the beverage into the containers is effected whilst the containers are located on a primary conveyor system and wherein the formulated mixture is delivered to the containers whilst the containers are positioned in a secondary conveyor system that is driven to divert the containers away from and back to the primary conveyor system prior to injection of the beverage into the containers. The method as claimed in claim 14 when dependent on claim 2 wherein the formulated mixture is delivered to respective ones of the containers by way of feed lines and injectors that are integrated in the secondary conveyor system.
- 16. The method as claimed in claim 14 when dependent on claim 3 wherein the formulated mixture is delivered to respective ones of the conveyors by way of a vibratory feeder and tablet releasing heads that are integrated in the secondary conveyor system. J:\Speci\300 399\300 349\34296.doc 11/05/99
- 17. The method of adding a probiotic bacteria to a beverage substantially as hereinbefore described with reference to the accompanying examples.
- 18. The method of adding a probiotic bacteria to a beverage substantially as hereinbefore described with reference to the accompanying drawings. J:\Speci\300 399\300 349\34296.doc 11/05/99
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU28098/99A AU2809899A (en) | 1997-03-18 | 1999-05-12 | Dosing beverage with a bacteria formulation |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPO5689 | 1997-03-18 | ||
| AU59357/98A AU5935798A (en) | 1997-03-18 | 1998-03-18 | Pasteurised liquid dairy milk with both prebiotic and probiotic properties and procedure for manufacturing thereof |
| AU28098/99A AU2809899A (en) | 1997-03-18 | 1999-05-12 | Dosing beverage with a bacteria formulation |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU59357/98A Division AU5935798A (en) | 1997-03-18 | 1998-03-18 | Pasteurised liquid dairy milk with both prebiotic and probiotic properties and procedure for manufacturing thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2809899A true AU2809899A (en) | 1999-07-22 |
Family
ID=25620522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU28098/99A Abandoned AU2809899A (en) | 1997-03-18 | 1999-05-12 | Dosing beverage with a bacteria formulation |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2809899A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7785635B1 (en) | 2003-12-19 | 2010-08-31 | The Procter & Gamble Company | Methods of use of probiotic lactobacilli for companion animals |
| US7906112B2 (en) | 2003-12-19 | 2011-03-15 | The Procter & Gamble Company | Canine probiotic Lactobacilli |
| US7998473B2 (en) | 2003-12-19 | 2011-08-16 | The Procter & Gamble Company | Methods of treatment or prevention of gastrointestinal disorders using canine probiotic bifidobacterium |
| US8034601B2 (en) | 2005-05-31 | 2011-10-11 | The Procter & Gamble Company | Feline probiotic bifidobacteria |
| US8809035B2 (en) | 2003-12-19 | 2014-08-19 | The Iams Company | Canine probiotic Bifidobacterium |
| US8877178B2 (en) | 2003-12-19 | 2014-11-04 | The Iams Company | Methods of use of probiotic bifidobacteria for companion animals |
| US9192177B2 (en) | 2005-05-31 | 2015-11-24 | The Iams Company | Feline probiotic Lactobacilli |
| US9771199B2 (en) | 2008-07-07 | 2017-09-26 | Mars, Incorporated | Probiotic supplement, process for making, and packaging |
| US10104903B2 (en) | 2009-07-31 | 2018-10-23 | Mars, Incorporated | Animal food and its appearance |
-
1999
- 1999-05-12 AU AU28098/99A patent/AU2809899A/en not_active Abandoned
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8894991B2 (en) | 2003-12-19 | 2014-11-25 | The Iams Company | Canine probiotic Lactobacilli |
| US8900569B2 (en) | 2003-12-19 | 2014-12-02 | The Iams Company | Method of treating diarrhea in a canine |
| US7998473B2 (en) | 2003-12-19 | 2011-08-16 | The Procter & Gamble Company | Methods of treatment or prevention of gastrointestinal disorders using canine probiotic bifidobacterium |
| US9821015B2 (en) | 2003-12-19 | 2017-11-21 | Mars, Incorporated | Methods of use of probiotic bifidobacteria for companion animals |
| US8802158B2 (en) | 2003-12-19 | 2014-08-12 | The Iams Company | Methods of use of probiotic Lactobacilli for companion animals |
| US8809035B2 (en) | 2003-12-19 | 2014-08-19 | The Iams Company | Canine probiotic Bifidobacterium |
| US7906112B2 (en) | 2003-12-19 | 2011-03-15 | The Procter & Gamble Company | Canine probiotic Lactobacilli |
| US8840880B2 (en) | 2003-12-19 | 2014-09-23 | The Iams Company | Canine probiotic bifidobacteria globosum |
| US7785635B1 (en) | 2003-12-19 | 2010-08-31 | The Procter & Gamble Company | Methods of use of probiotic lactobacilli for companion animals |
| US8877178B2 (en) | 2003-12-19 | 2014-11-04 | The Iams Company | Methods of use of probiotic bifidobacteria for companion animals |
| US8900568B2 (en) | 2003-12-19 | 2014-12-02 | The Iams Company | Method of treating diarrhea in a canine |
| US9192177B2 (en) | 2005-05-31 | 2015-11-24 | The Iams Company | Feline probiotic Lactobacilli |
| US8034601B2 (en) | 2005-05-31 | 2011-10-11 | The Procter & Gamble Company | Feline probiotic bifidobacteria |
| US9771199B2 (en) | 2008-07-07 | 2017-09-26 | Mars, Incorporated | Probiotic supplement, process for making, and packaging |
| US10709156B2 (en) | 2008-07-07 | 2020-07-14 | Mars, Incorporated | Pet supplement and methods of making |
| US10104903B2 (en) | 2009-07-31 | 2018-10-23 | Mars, Incorporated | Animal food and its appearance |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5421774B2 (en) | Apparatus and method for packaging beverages | |
| CN1046404C (en) | A refrigerated product containing pieces of chocolate and a process and an arrangement for its production | |
| AU2809899A (en) | Dosing beverage with a bacteria formulation | |
| RU2006118703A (en) | METHOD AND DEVICE FOR DOSED BOTTLING OF MULTILAYERED BY EXTERNAL TYPE OF DRINKS FROM LIQUID CONCENTRATES | |
| AU2005295023A1 (en) | Carbonated protein drink and method of making | |
| CN102266107A (en) | Composite prebiotics beverage and preparation method thereof | |
| CN101502288B (en) | Method for producing milk beverage with added garden stuff fiber | |
| CN109430382A (en) | It is a kind of to have effects that adjust the formula food and preparation method thereof of blood glucose | |
| US6447823B1 (en) | Liquid yogurt with encapsulated lactic acid bacteria and method for producing the same | |
| CN101990940B (en) | Fermented milk product and preparation method thereof | |
| JP2019081733A5 (en) | ||
| KR20010039427A (en) | Functional food containing yoghurt insoluble fiber for treating constipation | |
| US8993639B2 (en) | Compound and method for treatment of gastroesophageal reflux | |
| WO2018012578A1 (en) | Ghrelin secretion promotor | |
| CN108850156A (en) | A kind of probiotics solid beverage and preparation method thereof | |
| EP2537793B1 (en) | New filling method and apparatus therefore | |
| US20200283225A1 (en) | Apparatus, System and Method for Providing Enhanced Consumable Food Stuffs | |
| CZ38719U1 (en) | A composition of inoculation probiotic cultures for the controlled fermentation of food, pharmaceutical or veterinary products | |
| US20210060137A1 (en) | Nutrient compositions having enhanced bioavailability | |
| EP0932394B1 (en) | Vitamin product | |
| CZ36968U1 (en) | Composition of inoculum probiotic cultures for fermenting food, pharmaceutical or veterinary products | |
| KR20170087984A (en) | Pear beverge from lactobacillus and process for preparation thereof | |
| CN102239974B (en) | Suckling piglet growth promotion milk and preparation method thereof | |
| Trujillo et al. | Transition feeding | |
| CN120753308A (en) | Formula of yoghurt powder and whey protein powder composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |